With approvals for upadacitinib expected in the coming months, AbbVie Inc. has been making the case for its closely watched JAK1 inhibitor with long-term data demonstrating that the drug works better than its own mega-blockbuster Humira in keeping rheumatoid arthritis patients in clinical remission as well as improving their symptoms.
The US major presented new results from the SELECT-EARLY and SELECT-COMPARE Phase III trials at the European League Against Rheumatism...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
